Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NXP800 in Advanced Cancers and Ovarian Cancer
NCT05226507Phase 1Terminated
- Sponsor
- Nuvectis Pharma, Inc.
- Start
- Dec 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of NXP800 in solid tumor and ovarian cancer (3 arms), sponsored by Nuvectis Pharma, Inc. Primary endpoints: Number of patients with treatment related adverse events, clinical laboratory abnormalities, dose limiting toxicities and Estimates of disease response by RECIST v 1.1. Started Dec 2021; status: terminated.
02
Drugs
NXP800
03
Conditions
solid tumorovarian cancer
Beyond the preview
Go deeper on NCT05226507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05226507.